Mayo Clinic Proceedings Home

Medical Treatment of Benign Prostatic Hyperplasia: 5α-Reductase Inhibitors and α-Adrenergic Antagonists

      Benign prostatic hyperplasia (BPH), a nonmalignant neoplasm of the prostatic epithelial and stromal tissue, occurs commonly in elderly men. The “gold standard” of care for symptomatic BPH has been and remains transurethral resection of the prostate. This operation, however, like any surgical procedure, has associated morbidity and imposes an appreciable expense on the health-care system; therefore, enthusiasm for the development of medical therapies for the management of symptomatic BPH has been substantial. Currently, practicing physicians have two types of medications for the treatment of symptomatic BPH: 5α-reductase inhibitors and α-adrenergic antagonists. The former drugs inhibit the conversion of testosterone to the potent prostatic androgen dihydrotestosterone. As a result, the androgenic stimulation to the prostate gland is suppressed, and the size of the prostate is decreased by approximately 25%. In some patients, this outcome decreases the mechanical obstruction of the prostatic urethra and improves micturition. α-Adrenergic antagonists decrease the smooth muscle tone of the bladder neck, prostatic adenoma, and prostatic capsule. After these structures have been relaxed, resistance to urine flow through the prostatic urethra can be decreased, and obstructive voiding symptoms can be resolved. Although two distinctly different mechanisms are involved, both types of medications are effective for treating BPH. Thus, in 1993, transurethral resection of the prostate is no longer the only available therapeutic option. With the advent of medical therapies, internists and primary-care physicians will have more involvement in the care of patients with BPH than previously. Therefore, urologists and nonurologists must work together to serve the needs of patients with prostatism.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bartsch G
        • Müller HR
        • Oberholzer M
        • Rohr HP
        Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia.
        J Urol. 1979; 122: 487-491
        • Berry SJ
        • Coffey DS
        • Walsh PC
        • Ewing LL
        The development of human benign prostatic hyperplasia with age.
        J Urol. 1984; 132: 474-479
        • Isaacs JT
        • Coffey DS
        Etiology and disease process of benign prostatic hyperplasia.
        Prostate Suppl. 1989; 2: 33-50
        • Baron E
        • Angrist A
        Incidence of occult adenocarcinoma of the prostate after 50 years of age.
        Arch Pathol. 1941; 32: 787-793
        • Birkhoff JD
        Natural history of benign prostatic hypertrophy.
        in: Hinman Jr, F Benign Prostatic Hypertrophy. Springer-Verlag, New York1983: 5-9
        • National Center for Health Statistics
        • Graves EJ
        Detailed diagnoses and procedures, National Hospital Discharge Survey, 1987.
        Vital Health Stat [13]. 1989; 100: 295
        • Graversen PH
        • Gasser TC
        • Wasson JH
        • Hinman Jr, F
        • Bruskewitz RC
        Controversies about indications for transurethral resection of the prostate.
        J Urol. 1989; 141: 475-481
        • Walsh PC
        Benign prostatic hyperplasia.
        in: Walsh PC Gittes RF Perlmutter AD Stamey TA 5th ed. Campbell's Urology. Vol 2. Saunders, Philadelphia1985: 1248-1265
        • Mebust WK
        • Holtgrewe HL
        • Cockett ATK
        • Peters PC
        • Writing Committee
        Transurethral prostatectomy: immediate and postoperative complications; a cooperative study of 13 participating institutions evaluating 3,885 patients.
        J Urol. 1989; 141: 243-247
        • Holtgrewe HL
        • Mebust WK
        • Dowd JB
        • Cockett ATK
        • Peters PC
        • Proctor C
        Transurethral prostatectomy: practice aspects of the dominant operation in American urology.
        J Urol. 1989; 141: 248-253
        • Fowler FJ
        • Wennberg JE
        • Timothy RP
        • Barry MJ
        • Mulley Jr, AG
        • Hanley D
        Symptom status and quality of life following prostatectomy.
        JAMA. 1988; 259: 3018-3022
        • Roos NP
        • Wennberg JE
        • Malenka DJ
        • Fisher ES
        • McPherson K
        • Andersen TF
        • et al.
        Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia.
        N Engl J Med. 1989; 320: 1120-1124
        • Malenka DJ
        • Roos N
        • Fisher ES
        • McLerran D
        • Whaley FS
        • Barry MJ
        • et al.
        Further study of the increased mortality following transurethral prostatectomy: a chart-based analysis.
        J Urol. 1990; 144: 224-227
        • Huggins C
        • Stevens RA
        The effect of castration on benign hypertrophy of the prostate in man.
        J Urol. 1940; 43: 705-714
        • Griffin JE
        • Wilson JD
        Disorders of the testes and male reproductive tract.
        in: Wilson JD Foster DW Williams Textbook of Endocrinology. 7th ed. Saunders, Philadelphia1985: 259-311
        • Hawkins EF
        • Trachtenberg J
        • Hicks LL
        • Walsh PC
        Androgens and estrogen receptors in the canine prostate.
        J Androl. 1980; 1: 234-243
        • Trachtenberg J
        • Hicks LL
        • Walsh PC
        Androgen- and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia.
        J Clin Invest. 1980; 65: 1051-1059
        • Walsh PC
        • Madden JD
        • Harrod MJ
        • Goldstein JL
        • MacDonald PC
        • Wilson JD
        Familial incomplete male pseudohermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.
        N Engl J Med. 1974; 291: 944-949
        • Imperato-McGinley J
        • Guerrero L
        • Gautier T
        • Peterson RE
        Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism.
        Science. 1974; 186: 1213-1215
        • Stoner E
        The clinical development of a 5α-reductase inhibitor, finasteride.
        J Steroid Biochem Mol Biol. 1990; 37: 375-378
        • Brooks JR
        • Berman D
        • Glitzer MS
        • Gordon LR
        • Primka RL
        • Reynolds GF
        • et al.
        Effects of a new 5α-reductase inhibitor on size, histologic characteristics, and androgen concentrations of the canine prostate.
        Prostate. 1982; 3: 35-44
        • Brooks JR
        • Berman C
        • Primka RL
        • Reynolds GF
        • Rasmusson GH
        5α-Reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the rat.
        Steroids. 1986; 47: 1-19
        • Liang T
        • Heiss CE
        • Cheung AH
        • Reynolds GF
        • Rasmusson GH
        4-Azasteroidal 5α-reductase inhibitors without affinity for the androgen receptor.
        J Biol Chem. 1984; 259: 734-739
        • Brooks JR
        • Berman C
        • Games D
        • Giltinan D
        • Gordon LR
        • Malatesta PF
        • et al.
        Prostatic effects induced in dogs by chronic or acute oral administration of 5α-reductase inhibitors.
        Prostate. 1986; 9: 65-75
        • George FW
        • Johnson L
        • Wilson JD
        The effect of a 5α-reductase inhibitor on androgen physiology in immature male rat.
        Endocrinology. 1989; 125: 2434-2438
        • Stoner E
        • Finasteride Study Group
        The clinical effects of 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia.
        J Urol. 1992; 147: 1298-1302
        • Gormley GJ
        • Stoner E
        • Bruskewitz RC
        • Imperato-McGinley J
        • Walsh PC
        • McConnell JD
        • et al.
        The effect of finasteride in men with benign prostatic hyperplasia.
        N Engl J Med. 1992; 327: 1185-1191
        • McConnell JD
        Current medical therapy for benign prostatic hyperplasia: the scientific basis and clinical efficacy of finasteride and alpha blockers.
        in: Walsh PC Retik AB Stamey TA Vaughan Jr, ED Campbell's Urology Update. Series 3. Saunders, Philadelphia1992: 1-12
        • Kirby RS
        • Bryan J
        • Eardley I
        • Christmas TJ
        • Liu S
        • Holmes SAV
        • et al.
        Finasteride in the treatment of benign prostatic hyperplasia: a urodynamic evaluation.
        Br J Urol. 1992; 70: 65-72
        • Rittmaster RS
        • Stoner E
        • Thompson DL
        • Nance D
        • Lasseter KC
        Effect of MK-906, a specific 5α-reductase inhibitor, on serum androgens and androgen conjugates in normal men.
        J Androl. 1989; 10: 259-262
        • Presti Jr, JC
        • Fair WR
        • Andriole G
        • Sogani PC
        • Seidmon EJ
        • Ferguson D
        • et al.
        Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer.
        J Urol. 1992; 148: 1201-1204
        • Guess HA
        • Heyse JF
        • Gormley GJ
        The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia.
        Prostate. 1993; 22: 31-37
      1. Guess HA, Heyse JF, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on serum PSA concentrations in men with benign prostatic hyperplasia—results from the North American phase III clinical trials. Urol Clin North Am [in press]

        • Caine M
        The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy.
        J Urol. 1986; 136: 1-4
        • Raz S
        • Zeigler M
        • Caine M
        Pharmacologic receptors in the prostate.
        Br J Urol. 1973; 45: 663-667
        • Caine M
        • Raz S
        • Zeigler M
        Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck.
        Br J Urol. 1975; 47: 193-202
        • Lepor H
        • Gup DI
        • Baumann M
        • Shapiro E
        Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia.
        Urology. 1988 Dec; 32: 21-26
        • Shapiro E
        • Lepor H
        Alpha1 adrenergic receptors in canine lower genitourinary tissues: insight into development and function.
        J Urol. 1987; 138: 979-983
        • Caine M
        • Pfau A
        • Perlberg S
        The use of alpha-adrenergic blockers in benign prostatic obstruction.
        Br J Urol. 1976; 48: 255-263
        • Lepor H
        The emerging role of alpha-antagonists in the therapy of benign prostatic hyperplasia.
        J Androl. 1991; 12: 389-394
        • Fabricius PG
        • Weizert P
        • Dunzendorfer U
        • Hannaford JM
        • Maurath C
        Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial.
        Prostate Suppl. 1990; 3: 85-93
        • Lepor H
        • Meretyk S
        • Knapp-Maloney G
        The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia.
        J Urol. 1992; 147: 1554-1557
        • Lepor H
        • Auerbach S
        • Puras-Baez A
        • Narayan P
        • Soloway M
        • Lowe F
        • et al.
        A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.
        J Urol. 1992; 148: 1467-1474
        • Holme JE
        • Husted SE
        • Jacobsen F
        • Nørgaard JP
        • Wolf H
        • Christensen MM
        • et al.
        Doxazosin—a new, efficient and safe drug in the treatment of benign prostatic obstruction [abstract].
        J Urol. 1990; 143: 267A
        • Chapple CR
        • Carter P
        • Christmas TJ
        • Noble JG
        • Miller P
        • Kirby RS
        • et al.
        A three month double-blind placebo controlled study of doxazosin as treatment for benign prostatic bladder outlet obstruction [abstract].
        J Urol. 1992; 147: 366A
        • Hedlund H
        • Andersson K-E
        • Ek A
        Effects of prazosin in patients with benign prostatic obstruction.
        J Urol. 1983; 130: 275-278
        • Kirby RS
        • Coppinger SWC
        • Corcoran MO
        • Chapple CR
        • Flannigan M
        • Milroy EJG
        Prazosin in the treatment of prostatic obstruction: a placebo-controlled study.
        Br J Urol. 1987; 60: 136-142
        • Martorana G
        • Giberti C
        • Damonte P
        • Ciprandi G
        • Dirienzo W
        • Giuliani L
        The effect of prazosin in benign prostatic hypertrophy, a placebo controlled double-blind study.
        IRCS Med Sci. 1984; 12: 11-12
        • Chapple CR
        • Christmas TJ
        • Milroy EJG
        A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction.
        Urol Int. 1990; 45: 47-55
        • Le Duc A
        • Cariou G
        • Baron C
        • Cukier J
        • Quentel P
        • Faure G
        • et al.
        A multicenter, double-blind, placebo-controlled trial of the efficacy of prazosin in the treatment of dysuria associated with benign prostatic hypertrophy.
        Urol Int. 1990; 45: 56-62
        • Ramsay JWA
        • Scott GI
        • Whitfield HN
        A double-blind controlled trial of a new α-1 blocking drug in the treatment of bladder outflow obstruction.
        Br J Urol. 1985; 57: 657-659
        • Jardin A
        • Bensadoun H
        • Delauche-Cavallier MC
        • Attali P
        • BPH-ALF Group
        Alfuzosin for treatment of benign prostatic hypertrophy.
        Lancet. 1991; 337: 1457-1461
      2. Lepor H. Alpha blockade: present and future [Symposium on Advances in BPH: Medical Therapy and Basic Research]. Presented at the American Urological Association 87th annual meeting; 1992 May 10–14; Washington (DC)